Home >> Healthcare >> Targeted Drugs for Allergic Diseases Market

Global Targeted Drugs for Allergic Diseases Market Size,Trends, Growth Forecast to 2031

Category : Healthcare | Report Code : 275 | Pages : 141 | Oct 2024

Report Overview

Anaphylaxis is an inappropriate reaction of the immune system to normal harmless substances. It generally has a rapid onset, strong reaction, and rapid subsidence. It has obvious genetic tendencies and individual differences. Currently, the prevalence of allergic diseases is increasing rapidly worldwide, affecting approximately 25% of the global population. Abnormalities in type 2 immune pathways are important factors in inducing allergic diseases. Type 2 immune pathway refers to an inflammatory pathway in which Th2 cells (T helper 2) play a key role, and various cytokines such as IL-4, IL-5, IL-13, and TSLP are involved. Depending on where the inflammatory reaction occurs, abnormal type 2 immune pathways can induce different allergic diseases, such as skin (atopic dermatitis, chronic spontaneous urticaria, etc.), respiratory tract (chronic sinusitis, asthma, chronic obstruction, etc.) lung disease, etc.), digestive tract (eosinophilic esophagitis), cardiovascular (eosinophilic granulomatous vasculitis), etc. Biological targeted drugs mainly reduce the inflammatory response and activity of immune cells by binding to targets such as specific regulatory factors in the type 2 immune pathway; Small molecule targeted drugs include JAK inhibitors and TYK2 inhibitors, which exert immunomodulatory effects by blocking the JAK/STAT pathway. Compared with traditional anti-allergic drugs, targeted drugs have better efficacy in severe or drug-resistant patients, and the drugs themselves are safer, and have gradually become the mainstream trend in the development of anti-allergic drugs.

The global Targeted Drugs for Allergic Diseases market size is projected to grow from US$ 36340 million in 2024 to US$ 91900 million in 2030; it is expected to grow at a CAGR of 16.7% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Targeted Drugs for Allergic Diseases Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Allergic Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Allergic Diseases sales for 2023 through 2029. With Targeted Drugs for Allergic Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Allergic Diseases industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Allergic Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Allergic Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Allergic Diseases market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Allergic Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Allergic Diseases.

Global key players of Targeted Drugs for Allergic Diseases include Sanofi, AbbVie, Novartis, Incyte, Roche, etc. The top five players hold a share over 76%. North America is the largest market, and has a share about 68%, followed by Europe with share 18%. In terms of product type, IL-4R is the largest segment, occupied for a share of 37%. In terms of application, Asthma has a share about 35 percent.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Allergic Diseases market by product type, application, key players and key regions and countries.

Segmentation by Type:
    IL-4R
    TSLP
    IL-5
    JAK
    IgE
    IL-13
    Others

Segmentation by Application:
    Atopic Dermatitis
    Asthma
    Chronic Sinusitis with Nasal Polyps
    Chronic Obstructive Pulmonary Disease
    Others

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

Segmentation by Type:
    IL-4R
    TSLP
    IL-5
    JAK
    IgE
    IL-13
    Others

Segmentation by Application:
    Atopic Dermatitis
    Asthma
    Chronic Sinusitis with Nasal Polyps
    Chronic Obstructive Pulmonary Disease
    Others

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    Sanofi
    AbbVie
    Novartis
    Incyte
    Roche
    AstraZeneca
    GSK
    Eli Lilly and Company
    Amgen
    Pfizer
    Leo Pharma
    Teva
    Otsuka Pharmaceutical
    Mabpharm

Frequently Asked Questions?

Ans - The purpose of a Targeted Drugs for Allergic Diseases market research report is to provide data-driven insights and analysis on a Targeted Drugs for Allergic Diseases market. It helps businesses understand industry trends, competition, consumer behavior, market size, growth potential, and risks, supporting strategic decision-making.

Ans - Market research reports typically include both quantitative (market size, revenue, growth rates) and qualitative (trends, consumer preferences, competitive analysis) data. It often includes industry statistics, surveys, expert opinions, historical data, and future forecasts.

Ans - The forecast period typically for Targeted Drugs for Allergic Diseases market report spans the next 5 to 10 years. It includes projected market trends, growth opportunities, and potential challenges.

Ans - Yes, Analytic Insights Hub customization services, allowing businesses to focus on specific geographies, sectors, or market segments that are relevant to them.

Ans - The report highlights major trends such as technological innovations, consumer behavior shifts, regulatory changes, or emerging markets that may impact the industry?s growth.